Stascheit, Frauke and Grittner, Ulrike and Hoffmann, Sarah and Mergenthaler, Philipp and Schroeter, Michael and Ruck, Tobias and Pawlitzki, Mark and Blaes, Franz and Kaiser, Julia and Schara, Ulrike and Della-Marina, Adela and Thieme, Andrea and Hagenacker, Tim and Jacobi, Christian and Berger, Benjamin and Urban, Peter P. and Knop, Karl Christian and Schalke, Berthold and Lee, De-Hyung and Kalischewski, Petra and Wiendl, Heinz and Meisel, Andreas (2023) Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis. JOURNAL OF NEUROLOGY, 270 (1). pp. 1-12. ISSN 0340-5354, 1432-1459
Full text not available from this repository. (Request a copy)Abstract
Background Patients with myasthenia gravis (MG) are potentially prone for a severe COVID-19 course, but there are limited real-world data available on the risk associated with COVID-19 for patients with MG. Here, we investigate whether current immunosuppressive therapy (IST) influences the risk of SARS-CoV-2 infection and COVID-19 severity. Methods Data from the German myasthenia gravis registry were analyzed from May 2020 until June 2021 and included patient demographics, MG disease duration, comorbidities, current IST use, COVID-19 characteristics, and outcomes. Propensity score matching was employed to match MG patients with IST to those without, and multivariable binary logistic regression models were used to determine associations between IST with (1) symptomatic SARS-CoV-2 infection and (2) severe COVID-19 course, as measured by hospitalization or death. Results Of 1379 patients with MG, 95 (7%) patients (mean age 58 (standard deviation [SD] 18) presented with COVID-19, of which 76 (80%) received IST at time of infection. 32 patients (34%) were hospitalized due to COVID-19; a total of 11 patients (12%) died. IST was a risk factor for hospitalization or death in the group of COVID-19-affected MG patients (odds ratio [OR] 3.04, 95% confidence interval [CI] =1.02-9.06, p = 0.046), but current IST was not associated with a higher risk for SARS-CoV-2 infection itself. Discussion In this national MG cohort study, current IST use was a risk factor for a severe disease course of COVID-19 but not for SARS-CoV-2 infection itself. These data support the consequent implementation of effective strategies to prevent COVID-19 in this high-risk group.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ECULIZUMAB; IMPACT; Myasthenia gravis; COVID-19; Immunosuppressive therapies; Outcome; German myasthenia gravis registry |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 05 Mar 2024 13:52 |
| Last Modified: | 05 Mar 2024 13:52 |
| URI: | https://pred.uni-regensburg.de/id/eprint/58656 |
Actions (login required)
 |
View Item |
